Targeted News Service

City St George's Partners With Paradigm Biopharmaceuticals to Study Osteoarthritis Pain Drug Candidate
April 01, 2026

LONDON, England, April 1 -- City St George, University of London issued the following news:

* * *

City St George's partners with Paradigm Biopharmaceuticals to study osteoarthritis pain drug candidate

Leading pain researchers at City St George's are partnering with Paradigm Biopharmaceuticals, an Australian late-stage clinical development company, to test a drug that could provide a new treatment option for osteoarthritis.

By Lisa Jon . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your Affiliation	Government Newspaper / Media Business Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions or comments:

Click here for more information about our products

Existing Customer Login

Targeted News Service Document Request Form